Science Current Events | Science News | Brightsurf.com
 

Vaccine yielded encouraging long-term survival rates in certain patients with NSCLC

April 04, 2012
CHICAGO - Long-term follow-up of a phase II clinical trial showed encouraging survival in some patients with stage 3B/4 non-small cell lung cancer treated with belagenpumatucel-L, a therapeutic vaccine. The findings were presented here at the AACR Annual Meeting 2012, held March 31 - April 4.

"This is a novel immunotherapy that appears to show unusually long survival in some patients," said Lyudmila Bazhenova, M.D., associate clinical professor at the University of California-San Diego Moores Cancer Center in La Jolla, Calif.

These findings represent an updated long-term survival analysis on patients treated with belagenpumatucel-L, a cell-based allogeneic vaccine derived from four lung cancer cell lines. The open-label study included 75 patients with non-small cell lung cancer (NSCLC) - two patients with stage 2 disease, 12 with stage 3A, 15 with stage 3B and 46 with stage 4. The researchers randomly assigned patients to three dose cohorts: 1.25, 2.5 or 5 × 107 cells/injection.

For all patients, median survival was 14.5 months, and the five-year survival rate was 20 percent. The 40 patients with stage 3B/4 cancer enrolled in the second and third dose cohorts had a median survival of 15.9 months and a one-year survival rate of 61 percent, a two-year survival rate of 41 percent and a five-year survival rate of 18 percent.

Patients with stage 3B/4 nonprogressive disease after chemotherapy had a median survival of 44.4 months; five-year survival was 50 percent, which is "unheard of for patients with NSCLC," Bazhenova said.

In contrast, patients who progressed after front-line chemotherapy had a median survival rate of 14.1 months and a 9.1 percent five-year survival rate.

Bazhenova said that although these results are intriguing, they must be confirmed in a phase III clinical trial, which is currently under way in eight countries.

American Association for Cancer Research


Related Non-small Cell Lung Cancer Current Events and Non-small Cell Lung Cancer News Articles


Testing for EGFR mutations and ALK rearrangements is cost-effective in NSCLC
Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker-guided treatment is cost-effective compared with standard chemotherapy treatment without any molecular testing in the metastatic non-small cell lung cancer (NSCLC) setting in the United States.

Moffitt researchers develop novel approach to visualize, measure protein complexes in tumors
Cancer diagnosis and treatment decisions are often hampered by a lack of knowledge of the biological processes occurring within the tumor.

Stereotactic body radiation therapy plus chemotherapy improves survival among stage 4 lung cancer patients
A clinical trial that combined stereotactic body radiation therapy with a specific chemotherapy regimen more than doubled survival rates for certain stage 4 lung cancer patients, UT Southwestern Medical Center cancer researchers report.

More evidence for impact of lung cancer targeted therapy from trial
An international study involving Manchester researchers has found that for previously untreated lung cancer patients with a particular genetic change, a new targeted therapy is better than standard chemotherapy.

Immune checkpoint inhibitors may work in brain cancers
New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

Three drugs may be better than one for certain patients with advanced colorectal cancer
Patients with a form of advanced colorectal cancer that is driven by a mutated version of the BRAF gene have limited treatment options available. However, results from a multi-centre clinical trial suggest that the cancer may respond to a combination of three targeted drugs.

Race, hospital, insurance status affect lung cancer treatment
African Americans, Hispanics and those who receive care at a community hospital are all significantly less likely than other patients to receive treatment for early stage non-small cell lung cancer, according to a report in the Journal of Thoracic Oncology.

Scientists trigger self-destruct switch in lung cancer cells
UK scientists have found a drug combination that can trigger the self-destruct process in lung cancer cells - paving the way for new treatments, according to research that will be presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool next week.

Molecular tumor markers could reveal new therapeutic targets for lung cancer treatment
Analysis of 607 small cell lung cancer (SCLC) lung tumors and neuroendocrine tumors (NET) identified common molecular markers among both groups that could reveal new therapeutic targets for patients with similar types of lung cancer, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology.

Post-operative radiation therapy improves overall survival for patients with resected non-small cell lung cancer
Patients who received post-operative radiation therapy (PORT), radiation therapy after surgery, lived an average of four months longer when compared to the patients who had the same disease site, tumor histology and treatment criteria and who did not receive PORT, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology.
More Non-small Cell Lung Cancer Current Events and Non-small Cell Lung Cancer News Articles

Non-Small Cell Lung Cancer: Across the Continuum of Care

Non-Small Cell Lung Cancer: Across the Continuum of Care
by Asante Communications, LLC


This Clinical Resource Tool is structured around consensus statements developed by the Non-Small Cell Lung Cancer (NSCLC) Working Group, a panel of oncologists with particular expertise in the multidimensional care of patients with advanced lung cancer. Using a modified Delphi process, the NSCLC Working Group has consolidated published evidence and expert clinical experience on critical issues pertaining to the comprehensive assessment of patients with advanced NSCLC, formulation of appropriate treatment regimens, implementation of maintenance therapy, and therapeutic alliances among pathologists, oncologists, and pulmonologists. The consensus statements and accompanying resources are intended as a practical companion to current guidelines, helping clinicians individualize best-practice...

Living With A Diagnosis Of Lung Cancer

Living With A Diagnosis Of Lung Cancer
by Joan Schiller MD (Author)


"Living With a Diagnosis of Lung Cancer” is an easy-to-understand booklet written to help lung cancer patients understand their diagnosis and their options as they face the disease. Lung cancer claims more lives than breast, prostate, and colon cancers combined. In fact, over 288,000 people are diagnosed each year in the U.S. People with lung cancer often are told, "Get your affairs in order." But, there is hope for those diagnosed with lung cancer. Thanks to research advances, there are options available to patients diagnosed regardless of the stage of the disease. Much progress is being made with new treatments being developed and tested each day. This valued resource will help you know what questions to ask of your medical team and can help you understand your treatments...

21st Century Adult Cancer Sourcebook: Non-Small Cell Lung Cancer (NSCLC) - Clinical Data for Patients, Families, and Physicians

21st Century Adult Cancer Sourcebook: Non-Small Cell Lung Cancer (NSCLC) - Clinical Data for Patients, Families, and Physicians
by Progressive Management


Authoritative information and practical advice from the nation's cancer experts about non-small cell lung cancer (NSCLC) includes official medical data on signs, symptoms, early detection, diagnostic testing, risk factors and prevention, treatment options, surgery, radiation, drugs, chemotherapy, staging, biology, prognosis, and survival, with a complete glossary of technical medical terms and current references.

Starting with the basics, and advancing to detailed patient-oriented and physician-quality information, this comprehensive in-depth compilation gives empowered patients, families, caregivers, nurses, and physicians the knowledge they need to understand the diagnosis and treatment of non-small cell lung cancer (NSCLC).

Non-small cell lung cancer is a disease...

Non-Small Cell Lung Cancer: New Research (Cancer Etiology, Diagnosis and Treatments)

Non-Small Cell Lung Cancer: New Research (Cancer Etiology, Diagnosis and Treatments)
by Lina Pasquariello (Editor)




Medifocus Guidebook on: Non-Small Cell Lung Cancer

Medifocus Guidebook on: Non-Small Cell Lung Cancer
by Medifocus.com (Author), Elliot Jacob PhD. (Editor)


The MediFocus Guidebook on Non-Small Cell Lung Cancer is the most comprehensive, up-to-date source of information available. You will get answers to your questions, including risk factors of Non-Small Cell Lung Cancer, standard and alternative treatment options, leading doctors, hospitals and medical centers that specialize in Non-Small Cell Lung Cancer, results of the latest clinical trials, support groups and additional resources, and promising new treatments on the horizon. This one of a kind Guidebook offers answers to your critical health questions including the latest treatments, clinical trials, and expert research; high quality, professional level information you can trust and understand culled from the latest peer-reviewed journals; and a unique resource to find leading experts,...

Lung Cancer

Lung Cancer
by Jack A. Roth (Editor), Waun Ki Hong (Editor), Ritsuko U. Komaki (Editor)


The best and most concise single source for state-of-the-artdiagnosis and treatment of lung cancer –newly revised,updated, and expanded.

Lung cancer has long been the number-one cause of death from cancerevery year and the third most frequently diagnosed after breast andprostate cancers. In 2010, about 15% of all cancer diagnoses and30% of all cancer deaths were due to lung cancer. Needless to say,there is a great need for more rapid advancements in diagnosis andtreatment of this devastating disease.Here is the comprehensively revised, updated, and expandededition of the well-established, evidence-based reference book thatdeals with the most recent advances in lung cancer prevention,screening, diagnosis, research, and treatment for the clinician.Edited and authored by leading...

When God & Cancer Meet

When God & Cancer Meet
by Lynn Eib (Author)


A book of powerful stories about cancer patients and their families who have been touched by God in miraculous ways—some in their bodies, others in their minds, all in their spirits—offers inspiring testimony that, when God and cancer meet, cancer is conquered. The author, herself a cancer survivor, gives us a behind-the-scenes glimpse of 18 personal encounters with God.

Here's what others are saying about When God & Cancer Meet:
“Lynn has captured the essence of hope in this book; captured hope in ways that I have always taught in my professional world as well as in my spiritual community. This book is a treasure to those who struggle with the fears of cancer and I want to keep it close at hand for those reasons.”

—Judy Lentz, RN, MSN, OCN, NHA...

Systemic Treatment of Non-Small Cell Lung Cancer (Oxford Oncology Library)

Systemic Treatment of Non-Small Cell Lung Cancer (Oxford Oncology Library)
by Giuseppe Giaccone (Author)


Lung cancer is the leading cause of cancer mortality worldwide, and non-small cell lung cancer (NSCLC) accounts for about 85% of all cases of lung cancer. Most patients present with advanced disease and five-year survival is low at about 15%. Surgery is the main treatment for early stage disease. If patients are deemed inoperable, systemic chemotherapy is considered. For patients with locally advanced disease, multimodality therapy is administered where chemotherapy is given in combination with definitive radiation therapy or surgery in selected cases. Cytotoxic chemotherapy regimens mainly consist of a platinum doublet. Biologic agents are increasingly being incorporated into treatment regimens.

This pocketbook summarises the latest evidence-based and practical information on the...

What You Need to Know About Non-Small Cell Lung Cancer - It's Your Life, Live It!

What You Need to Know About Non-Small Cell Lung Cancer - It's Your Life, Live It!
by Cancer Group Institute


Selecting the right treatment can literally make the difference between life and death. It is important to have the peace-of-mind knowing that you have done everything possible to help fight Non-Small Cell Lung cancer successfully.

The Cancer Group Institute's book explains, in plain English, the definition, types, frequency, risk factors, symptoms, historic and latest effective treatment for Non-Small Cell Lung cancer. We describe surgery, radiation, chemotherapy and immune therapies. We tell you everything you must know to help make the right choices today for a Non-Small Cell Lung cancer problem.

We are honored to inform you that many leading hospitals use our books in their medical library to be used by physicians. They are Harvard University, Columbia, NYU, ...

Local Nonsurgical Therapies for Stage I and Symptomatic Obstructive Non-Small-Cell Lung Cancer: Comparative Effectiveness Review Number 112

Local Nonsurgical Therapies for Stage I and Symptomatic Obstructive Non-Small-Cell Lung Cancer: Comparative Effectiveness Review Number 112
by U.S. Department of Health and Human Services (Author), Agency for Healthcare Research and Quality (Author)


Non–small-cell lung cancer (NSCLC) refers to any type of epithelial lung cancer other than small-cell lung cancer. The disease arises from epithelial cells of the lung, from the central bronchi to terminal alveoli. The histological type correlates with site of origin, reflecting the variation in respiratory tract epithelium by location. The most common types of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Several other types occur less frequently; all can occur in unusual histological variants. Squamous cell carcinoma typically originates near a central bronchus. Adenocarcinoma and adenocarcinoma in situ (formerly called bronchioalveolar carcinoma) usually arise in peripheral lung tissue. Adenocarcinomas are frequently associated with cigarette smoke but...

© 2015 BrightSurf.com